Thursday 15 October 2026
Export ELDN’s income statement to Excel — free account
Eledon Pharmaceuticals, Inc.
ELDN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 107.7% and free cash flow fell 28.0%, each against the same quarter a year earlier.
2.27
0.02
+0.89%
Follow ELDN
Eledon Pharmaceuticals, Inc. (ELDN) P/E ratio
Eledon Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 6.2× (July 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 6.2×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LYEL Lyell Immunopharma, Inc. compare | n/m |
| ELDN Eledon Pharmaceuticals, Inc. | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| UPB Upstream Bio, Inc. compare | n/m |
| RNAC Cartesian Therapeutics, Inc. compare | n/m |
| IVVD Invivyd, Inc. compare | n/m |
| ACOG Alpha Cognition Inc. compare | n/m |
| PRQR ProQR Therapeutics N.V. compare | n/m |
| CGEN Compugen Ltd. compare | 5.5× |
| Biotechnology industry median | 8.4× |
| Healthcare sector median | 22.8× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)